Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus

European Journal of Immunology

Volumn 43, Issue 3, 2013, Pages 641-648

  Buricchi, Francesca ^a   Bardelli, Monia ^a   Malzone, Carmine ^a   Capecchi, Barbara ^a   Nicolay, Uwe ^b   Fragapane, Elena ^a   Castellino, Flora ^a   Del Giudice, Giuseppe ^a   Galli, Grazia ^a   Finco, Oretta ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Biostatistics Novartis Vaccines and Diagnostics   (Germany)

Author keywords

Cross reactive antibodies; H5N1; Influenza; Memory B cells; Vaccination

Indexed keywords

AVIAN INFLUENZA VACCINE; MIFAMURTIDE; NEUTRALIZING ANTIBODY;

ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ARTICLE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MEMORY CELL; PRIORITY JOURNAL; VIRUS STRAIN;

ADULT; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84874987465     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242563     Document Type: Article

References (25)

1. Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. and Kawaoka, Y., Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992. 56: 152-179.
2. Carrat, F. and Flahault, A., Influenza vaccine: the challenge of antigenic drift. Vaccine 2007. 25: 6852-6862.
3. Neumann, G., Chen, H., Gao, G. F., Shu, Y. and Kawaoka, Y., H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 2010. 20: 51-61.
4. Lopez, P., Caicedo, Y., Sierra, A., Tilman, S., Banzhoff, A. and Clemens, R., Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 2011. 203: 1719-1728.
5. Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E. and Zambon, M. C., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001. 357: 1937-1943.
6. Stephenson, I., Nicholson, K. G., Colegate, A., Podda, A., Wood, J., Ypma, E. and Zambon, M., Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003. 21: 1687-1693.
7. Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C. and Katz, J. M., Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 2005. 191: 1210-1215.
8. Atmar, R. L., Keitel, W. A., Patel, S. M., Katz, J. M., She, D., El, S. H., Pompey, J. et al., Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 2006. 43: 1135-1142.
9. Stephenson, I., Gust, I., Pervikov, Y. and Kieny, M. P., Development of vaccines against influenza H5. Lancet Infect. Dis. 2006. 6: 458-460.
10. Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Drame, M., Clement, F., Hons, E., Devaster, J. M. et al., Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007. 370: 580-589.
11. Gioia, C., Castilletti, C., Tempestilli, M., Piacentini, P., Bordi, L., Chiappini, R., Agrati, C. et al., Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis. 2008. 14: 121-128.
12. Corti, D., Suguitan, A. L., Jr., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C. et al., Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010. 120: 1663-1673.
13. + memory B cells. PLoS. One 2008. 3: e3942.
14. Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N. Y. et al., Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008. 453: 667-671.
15. Wang, T. T., Tan, G. S., Hai, R., Pica, N., Petersen, E., Moran, T. M. and Palese, P., Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS. Pathog. 2010. 6: e1000796.
16. Ekiert, D. C., Friesen, R. H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C. et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011. 333: 843-850.
17. Wrammert, J., Koutsonanos, D., Li, G. M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M. et al., Broadly cross-reactive antibodies dominate the human B-cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011. 208: 181-193.
18. Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G. et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011. 333: 850-856.
19. + T-cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 2009. 106: 3877-3882.
20. Alberini, I., Del Tordello, E., Fasolo, A., Temperton, N. J., Galli, G., Gentile, C., Montomoli, E. et al., Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009. 27: 5998-6003.
21. Bernstein, D. I., Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K., Graham, I. L., Noah, D. L. et al., Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 2008. 197: 667-75.
22. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J. et al., Antibody recognition of a highly conserved influenza virus epitope. Science 2009. 324: 246-251.
23. Khurana, S., Suguitan, A. L., Jr., Rivera, Y., Simmons, C. P., Lanzavecchia, A., Sallusto, F., Manischewitz, J. et al., Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS. Med. 2009. 6: e1000049.
24. Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T. et al., Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010. 2: 15ra5.
25. Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G. et al., MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 2011. 3: 85ra48.